Goldman Sachs
-
Matthew Westerman and Julian Metherell, who both spent over 10 years as partners at Goldman Sachs, will run a new private investment firm together with Greek shipping tycoon, Peter Livanos,
-
SSA borrowers are streaming into the euro market, flooding the early part of the week with deals in an effort to secure funding before a slew of central bank meetings towards the end of the week. -
Deutsche Bank is losing its head of Asia equity-linked business, with Keyvan Zolfaghari set to leave the firm for Goldman Sachs.
-
-
Quantitative easing, perhaps the single most important factor affecting bond prices over the past three years, could be coming to a long awaited end this year. Members of the European Central Bank governing council seemed to hint as much this week, causing govvie spreads to gap wider, writes Lewis McLellan.
-
Corporate bond issuers enjoyed tighter spreads and strong order books amid an improvement in issuance conditions as they jumped back into the dollar market this week.
-
Against seemingly insurmountable odds, Italian industrial company Carel has managed to price its initial public offering during a political crisis which has forced companies across the board to postpone or cancel deals.
-
Hong Kong was a hotbed of accelerated bookbuild activity this week as two biotechnology firms and a property developer raised a combined HK$6.7bn ($854m) in primary and secondary equity.
-
Puxin and VCredit Holdings, both of which launched IPOs earlier this week, were covered on their first day of bookbuilding.
-
Xiaomi Corp had its listing hearing with the Hong Kong Stock Exchange on Thursday, paving the way for investor education to begin on Monday if the IPO is approved.
-
UBS appoints Asia DCM syndicate heads – BNP’s SEA loan syndicate head to relocate – Morgan Stanley’s ECM co-head dies at 41 – Goldman DCM banker moves to Macquarie – CMS’s Chien moves to buy-side – Citi builds Oz team – Wong leaves HSBC
-
Hua Medicine has filed for an IPO in Hong Kong under sponsors CLSA and Goldman Sachs, as the promised pipeline of biotechnology issuers begins to materialise following the city’s new listing rules.
